Skip to main content
    K

    Kazia Therapeutics Ltd ADR (KZIA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.60
    -1.02 (-15.41%)

    Market Cap: $75.65M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Kazia Therapeutics Ltd ADR (KZIA) Financials: Revenue, Profit and Cash Flow

    Updated Mar 16, 2026. Financial statements from company filings, amounts in AUD.

    Kazia Therapeutics Ltd ADR reported revenue of AUD 42.00K for the fiscal year ended Jun 30, 2025, down 98.2% from the year before. That year, net income was AUD -20.70M with a net margin of -49290.5%, operating cash flow was AUD -13.28M and free cash flow was AUD -13.28M. The quarter ended Dec 31, 2025 had net income of AUD -12.32M.

    Revenue and Margins

    Over the 9 years to Jun 2025, revenue fell from AUD 4.07M, a compound annual decline of 39.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 202542.00K-98.2%100.0%-33850.0%-49290.5%
    Jun 20242.31M+415755.9%100.0%-1233.2%-1160.2%
    Jun 2023555-94.5%100.0%-4346661.1%-3687419.8%
    Jun 202210.00K-99.9%100.0%-253990.0%-250140.0%
    Jun 202115.18M+1436.6%100.0%-42.0%-55.5%
    Jun 2020988.11K+63038.0%100.0%-1234.3%-1261.7%
    Jun 20191.56K-88.1%100.0%-535463.3%-656230.0%
    Jun 201813.11K-99.9%100.0%-95262.4%-46071.1%
    Jun 20178.79M+115.9%100.0%-123.5%-121.4%
    Jun 20164.07MN/A100.0%-313.7%-296.3%
    Annual, fiscal years ended Jun 2016 to Jun 2025

    Income Statement

    In the fiscal year ended Jun 2025, the net loss narrowed from the year before. In the quarter ended Dec 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemJun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017Jun 2016
    Revenue42.00K2.31M55510.00K15.18M988.11K1.56K13.11K8.79M4.07M
    Gross profit42.00K2.31M55510.00K15.18M988.11K1.56K13.11K8.79M4.07M
    Research and development7.33M17.38M15.56M20.17M14.54M9.49M6.48M9.77M11.14M9.89M
    Operating income-14.22M-28.46M-24.12M-25.40M-6.38M-12.20M-8.38M-12.49M-10.85M-12.77M
    Net income-20.70M-26.78M-20.47M-25.01M-8.42M-12.47M-10.27M-6.04M-10.67M-12.06M
    EBITDA-13.28M-26.59M-22.28M-23.52M-5.11M-11.11M-7.71MN/A-9.44M-11.72M
    Fiscal years ended Jun 2016 to Jun 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Dec 2024Sep 2024Jun 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    RevenueN/A19.71K19.71K22.29K2.48M2.48M51.00KN/A278N/AN/A
    Gross profitN/A19.71K19.71K22.29K2.48M2.48M51.00KN/A278-626.20K-671.83K
    Operating income-13.30M-4.85M-4.85M-9.37M-19.58M-19.58M-8.88M-10.51MN/A-5.26M-13.64M-25.38M
    Net income-12.32M-9.95M-9.95M-10.45M-17.95M-17.95M-8.82M-6.88MN/A-3.44M-13.59M-11.81M
    Last 12 quarters

    Balance Sheet

    As of Jun 2025, cash and equivalents exceeded short-term debt of AUD 396.00K by 3.95M. Shareholder equity was negative, at -8.30M, as total liabilities of 14.36M exceeded total assets of 6.06M.

    Annual

    Line itemJun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017Jun 2016
    Total assets6.06M21.59M28.08M35.89M58.09M23.06M21.18M28.18M35.91M35.52M
    Current assets4.93M6.14M10.77M9.45M29.39M10.65M7.54M9.26M19.48M34.09M
    Cash and equivalents4.34M1.66M5.24M7.36M27.59M8.76M5.43M5.96M14.45M33.45M
    Total liabilities14.36M31.60M16.03M17.61M20.24M8.94M7.01M8.93M10.57M1.59M
    Short-term debt396.00K634.00K1.80M1.84MN/AN/A084.00K10.00K10.00K
    Shareholder equity-8.30M-10.02M12.05M18.27M37.85M14.13M14.20M19.24M25.34M33.93M
    Fiscal years ended Jun 2016 to Jun 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Dec 2024Sep 2024Jun 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total assets71.04M6.06M6.06M17.91M21.59M21.59M24.38M28.08M28.09MN/A27.84M35.89M
    Total liabilities24.62M14.36M14.36M21.72M31.60M31.60M19.12M16.03M16.03MN/A16.25M17.61M
    Cash and equivalents69.39M4.34M4.34M3.06M1.66M1.66M3.56M5.24M5.24MN/A4.39M7.36M
    Shareholder equity46.42M-8.30M-8.30M-3.81M-10.02M-10.02M5.27M12.05M12.05MN/A11.58M18.27M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2025.

    Annual

    Line itemJun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017Jun 2016
    Operating cash flow-13.28M-9.58M-15.16M-22.76M-9.11M-8.81M-6.71M-8.66M-11.43M-11.98M
    Capital expenditures0000000011.65K525.00K
    Free cash flow-13.28M-9.58M-15.16M-22.76M-9.11M-8.81M-6.71M-8.66M-11.45M-12.51M
    Investing cash flowN/AN/AN/A-2.37M-2.36M-2.36M2.36M150.00K-7.12M-522.00K
    Financing cash flow15.98M5.99M12.97M3.73M28.11M12.14M3.82M3.82M-17.66K782.00K
    Fiscal years ended Jun 2016 to Jun 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Dec 2024Sep 2024Jun 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-9.07M-4.14M-4.14M-4.21M-3.25M-3.25M-6.33M-6.35M-3.18M-3.18M-8.81M
    Capital expendituresN/A4.14M4.14M00000000
    Free cash flowN/A-8.28M-8.28M-4.21M-3.25M-3.25M-6.33M-6.35M-3.18M-3.18M-8.81M
    Last 11 quarters

    Frequently Asked Questions About KZIA

    What is Kazia Therapeutics Ltd ADR's annual revenue?

    Kazia Therapeutics Ltd ADR reported revenue of AUD 42.00K for the fiscal year ended Jun 30, 2025.

    How fast is Kazia Therapeutics Ltd ADR's revenue growing?

    Revenue was down 98.2% for the fiscal year ended Jun 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 61.3%.

    Is Kazia Therapeutics Ltd ADR profitable?

    No. Kazia Therapeutics Ltd ADR reported net income of AUD -20.70M for the fiscal year ended Jun 30, 2025, with a net margin of -49290.5%.

    How much free cash flow does KZIA generate?

    For the fiscal year ended Jun 30, 2025, operating cash flow of AUD -13.28M minus capital expenditures of AUD 0 produced free cash flow of AUD -13.28M.

    How much debt does Kazia Therapeutics Ltd ADR have?

    The balance sheet dated Jun 30, 2025 reported short-term debt of AUD 396.00K and cash and equivalents of AUD 4.34M.